Literature DB >> 15480782

Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer.

Michael Stahl1, Hansjochen Wilke, Martin Stuschke, Martin K Walz, Ulrich Fink, Michael Molls, J Rüdiger Siewert, Michael Schroeder, Hans-Bruno Makoski, Ulrich Schmidt, Siegfried Seeber, Udo Vanhoefer.   

Abstract

PURPOSE: From 1991 to 1994 we performed a phase II study with intensive preoperative chemoradiation in locally advanced squamous cell carcinoma and adenocarcinoma of the esophagus. We now report on a multivariate analysis of prognostic factors based on the long-term results at a median follow-up of 6.5 years. PATIENTS AND METHODS: Eighty-eight patients were treated. Prognostic factors for overall survival and local tumor control were identified by univariate and multivariate analysis.
RESULTS: Median overall survival reached 17 months, and the survival rate at 5 years was 22% (95%-confidence interval: 18-26%). Response to induction chemotherapy was the only independent factor predicting local tumor control and--beside weight loss prior to treatment--it also proved to be an independent prognostic factor for long-term survival.
CONCLUSIONS: Intensive chemoradiation followed by surgery seems to be appropriate to improve long-term survival of high-risk patients with locally advanced esophageal cancer. In our trial, local tumor control and prognosis were best correlated with response to induction chemotherapy. These results may help to guide decisions regarding surgery in multimodal treatment of EC. Further efforts are needed to increase the number of treatment responders and to predict tumors not responding to chemo(radio)therapy earlier.

Entities:  

Mesh:

Year:  2004        PMID: 15480782     DOI: 10.1007/s00432-004-0604-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

2.  Does neoadjuvant chemoradiation downstage esophageal carcinoma?

Authors:  M S Slater; J Holland; D O Faigel; B C Sheppard; C W Deveney
Journal:  Am J Surg       Date:  2001-05       Impact factor: 2.565

3.  Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study.

Authors:  E P Alexander; T Lipman; J Harmon; R Wadleigh
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

4.  Stage II esophageal carcinoma: the significance of T and N.

Authors:  W A Killinger; T W Rice; D J Adelstein; S V Medendorp; G Zuccaro; T J Kirby; J R Goldblum
Journal:  J Thorac Cardiovasc Surg       Date:  1996-05       Impact factor: 5.209

5.  Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.

Authors:  M Stahl; H Wilke; U Fink; M Stuschke; M K Walz; J R Siewert; M Molls; W Fett; H B Makoski; N Breuer; U Schmidt; W Niebel; H Sack; F W Eigler; S Seeber
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

6.  A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.

Authors:  J A Ajani; R Komaki; J B Putnam; G Walsh; J Nesbitt; P W Pisters; P M Lynch; A Vaporciyan; R Smythe; S Lahoti; I Raijman; S Swisher; F D Martin; J A Roth
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

7.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

8.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

9.  Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.

Authors:  D J Adelstein; T W Rice; L A Rybicki; M A Larto; J Ciezki; J Saxton; M DeCamp; J J Vargo; J A Dumot; G Zuccaro
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

10.  Selection of patients for curative or palliative resection of esophageal cancer based on preoperative endoscopic ultrasonography.

Authors:  J H Peters; S F Hoeft; J Heimbucher; R M Bremner; T R DeMeester; C G Bremner; G W Clark; M Kiyabu; Y Parisky
Journal:  Arch Surg       Date:  1994-05
View more
  16 in total

1.  Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.

Authors:  Mathieu Hatt; Adrien Le Pogam; Dimitris Visvikis; Olivier Pradier; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

Review 2.  [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy].

Authors:  F Lordick; K Ott; A Sendler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

3.  Risk factors associated with early recurrence of adenocarcinoma of gastroesophageal junction after curative resection.

Authors:  Guodong Wang; Aiwen Wu; Xiaojing Cheng; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

4.  Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.

Authors:  Akihiro Suzuki; Lianchun Xiao; Yuki Hayashi; Homer A Macapinlac; James Welsh; Steven H Lin; Jeffrey H Lee; Manoop S Bhutani; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

5.  Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.

Authors:  Mathieu Hatt; Dimitris Visvikis; Olivier Pradier; Catherine Cheze-le Rest
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

6.  The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

7.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

8.  Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients.

Authors:  S Shen; J L Araujo; N K Altorki; J R Sonett; A Rodriguez; K Sungur-Stasik; C F Spinelli; A I Neugut; J A Abrams
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

Review 9.  Pneumo-CT assessing response to neoadjuvant therapy in esophageal cancer: Imaging-pathological correlation.

Authors:  Marina Ulla; Ernestina Gentile; Ezequiel Levy Yeyati; Maria L Diez; Demetrio Cavadas; Ricardo D Garcia-Monaco; Pablo R Ros
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

Review 10.  [Principles of neoadjuvant therapy].

Authors:  F Lordick
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.